M Bronstein, University of São Paulo Medical School, Brazil

The efficacy and safety of pasireotide LAR (40 mg), a multi-receptor targeted somatostatin analogue with high affinity for somatostatin receptor subtypes 1, 2, 3 and 5, will be assessed in 359 patients from 116 sites in 27 countries with active acromegaly versus octreotide LAR (20 mg). Patients will be dosed once every 28 days for 12 months, with titrations at 3 and 7 months as required. Results from this large, randomised, Phase III study will help determine the efficacy and safety of pasireotide LAR in the treatment of patients with active acromegaly.